Specialised Therapeutics welcomes the registration of YORVIPATH by the Therapeutic Goods Administration, “for the treatment of chronic hypoparathyroidism in adults”. YORVIPATH was granted an ...

The company has already demonstrated strong revenue growth of 36.34% over the last twelve months. The 2025 consensus estimates for Yorvipath revenue vary, with VA consensus at €232 million and F ...

SINGAPORE, Feb. 21, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH ® (palopegteriparatide) by the Therapeutic Goods ...

Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical ...

Yorvipath saw 908 U.S. prescriptions by Feb. 7, 2025, while Skytrofa sales hit €58.5M. The board approved a $18.25M share repurchase plan. Every week, our Whisper Index uncovers five overlooked ...

SINGAPORE, Feb. 20, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by the Therapeutic ...

Leading Australian Endocrinologist and Head of the School of Clinical Sciences at Monash Health, Professor Peter Ebeling AO, applauded the TGA approval of YORVIPATH in addressing an unmet medical need ...

With Yorvipath showing potential for a strong launch in 2025, Goldman Sachs maintains the Buy rating and raises the price target to $225 from $200. Price Action: ASND stock is up 15.8% at $146.08 ...

The increase was primarily due to Novo Nordisk A/S’s (NYSE:NVO) $100 million upfront fee and the EU launch of Yorvipath. TransCon hGH (lonapegsomatropin, marketed as Skytrofa) sales reached 58.5 ...